Here, we evaluated how clinical features like tumor load and overall survival differ between patients with metastatic colorectal cancer (mCRC) carrying distinct somatic KRAS G12, G13, Q61, K117, or A146 mutations. The gene discussed is KRAS; the disease is neoplasm.